Report #2857688

Overview

Sex

Male

Age

Age unknown

State

CA

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (2)

Symptom narrative

after administering Boostrix intravenously instead of intramuscularly to a patient; receive a double dose of a Boostrix vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a male patient who received DTPa (Reduced antigen) (Boostrix) (batch number M2G3Z, expiry date 11-JUL-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix (intravenous) and Boostrix. On an unknown date, an unknown time after receiving Boostrix and not applicable after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: after administering Boostrix intravenously instead of intramuscularly to a patient) and overdose (Verbatim: receive a double dose of a Boostrix vaccine). The outcome of the intramuscular formulation administered by other route and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.